Case Report

Meningioangiomatosis without neurofibromatosis simulating encephalitis in neuroimaging

Everton Barbosa-Silva, Marcos Dellaretti, Gervásio Teles C. de Carvalho, Júlio Leonardo Barbosa Pereira, Laelson Botrel Jr, José Eymard H. Pittella, Atos Alves de Sousa

Department of Neurosurgery, Santa Casa Hospital de Belo Horizonte, MG, Department of Pathology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil

E-mail: Everton Barbosa-Silva - everneuro@gmail.com; Marcos Dellaretti - mdellaretti@mac.com; Gervásio Teles C. de Carvalho - gervasioteles@gmail.com; Júlio Leonardo Barbosa Pereira - jdui.pereira@me.com; Laelson Botrel Jr - laelsonb@hotmail.com; José Eymard H. Pittella - jehpittella@hotmail.com; Atos Alves de Sousa - sousatos@hotmail.com

*Corresponding author

Received: 18 December 11 Accepted: 5 March 12 Published: 19 March 12

Copyright: © 2012 Barbosa-Silva E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

INTRODUCTION

Meningioangiomatosis (MA) is a rare entity characterized by a focal lesion that affects the leptomeninges and the cerebral cortex. It can be misdiagnosed as a brain tumor both clinically and radiologically and is usually associated with hamartomatos focal lesions. MA is considered benign, with no reports of malignancy until now, but its histogenesis remains uncertain. [6]

MA was initially described in patients presenting type 2 neurofibromatosis (NF2) in whom it is clinically silent and often diagnosed at autopsy. [4,12] A few cases have been published on patients without NF2, usually presenting with medically refractory seizures, which usually improve after total resection of the lesion. Most of those patients had a single lesion characterized by meningovascular proliferation and leptomeningeal calcifications. [4]

The present paper reports a patient diagnosed with MA not associated with hamartomatous lesions or NF2.

CASE REPORT

A 32-year-old man was admitted with simple partial seizures described as left hemifacial and left arm...
automatisms, which he reported having had for 1 week. Clinical and neurological examinations were normal and he presented no signs or symptoms of NF2.

The patient developed status epilepticus, being initially treated with endovenous phenytoin and diazepam. He was transferred to the intensive care unit (ICU), so as to better control his seizures. Computerized tomography (CT) scan showed a right frontal nonenhancing hypodense lesion. Magnetic resonance images (MRI) revealed an extensive parieto-occipital lesion and another right frontal lesion, initially suggestive of encephalitis [Figure 1].

Liquor lab tests were normal. An open biopsy of the meninges and brain was performed via a right parieto-occipital craniotomy. The histopathologic diagnosis, complemented by immunohistochemical studies, was MA, characterized by diffuse proliferation of elongated perivascular, fibroblast-like cells in the cerebral cortex [Figure 2]. Immunostaining of smooth muscle actin or epithelial membrane antigen in the perivascular cells was not observed; however, immunostaining of CD34, a marker for endothelial cells, was positive only in the endothelial cells that normally cover the intima [Figure 3]. The cytoarchitecture of the cerebral cortex was normal, but selective neuronal ischemic necrosis of isolated cells and reactive fibrillary astrocytosis were observed. The meninges sample was also normal.

Continuous sedation was necessary and kept for 28 days so as to control the seizures. After this period, the patient left the ICU, being medicated with phenytoin (500 mg/day), clonazepam (2 mg/day), and valproic acid (1500 mg/day). He had important neurological sequelae caused by ischemic lesions due to the status epilepticus. The patient was seizure-free for 3 months. Thereafter, seizures recurred, remaining refractory to antiepileptic drugs and the patient died.

**DISCUSSION**

MA was originally described in 1915 as an incidental finding during autopsy, associated with NF2. However, the nomenclature was only established in 1937.[2,18] MA most commonly affects children and young adults and the most usual clinical manifestations are refractory seizures and headache.

Even though its histology is unique, its histogenesis and pathogenesis remain controversial.[14] Three hypotheses have been proposed: a) the lesion is a hamartoma that results in degenerative alterations in the encephalic parenchyma; b) the lesion is caused by the invasion of the cerebral cortex by a leptomeningeal meningioma; c) the lesion is a vascular malformation involving secondary proliferation of meningeal cells.[3,7,9]
MA affects the cerebral cortex of the frontal and temporal lobes in approximately 90% of all cases, though it is occasionally observed in deep encephalic structures. In patients without NF2, the lesion is usually a single, solid, well-defined mass that presents slow growth.

Multiple lesions tend to occur in patients with NF2 and can vary from microscopic lesions to large, macroscopically visible nodules. Radiological findings are nonspecific, while computed tomography (CT) scans show different characteristics from isodense to slightly hyperdense images, with or without calcifications. Magnetic resonance imaging (MRI) also reveals different characteristics. This wide spectrum in the imaging exams makes clear clinical diagnosis difficult. In the present case, MRI showed an extensive parieto-occipital lesion and another frontal right lesion, giving the initial impression of a patient with diffuse encephalic compromise suggestive of encephalitis.

The main histological characteristic of MA is meningovascular proliferation interlaced with layers of fibrous tissue associated with leptomeningeal calcification. The histological spectrum can vary expressively, from cellular to vascular predominance, which may correspond to the evolutive stages of MA.

In the present case, only angiomatoid microvascular proliferation was observed associated with diffuse perivascular proliferation of elongated, fibroblast-like cells that affected the cerebral cortex, with no leptomeningeal calcifications. Immunohistochemistry has limited diagnostic value in MA due to variable staining patterns. In the case presented, immunostaining for epithelial membrane antigen, a meningothelial cell marker, was negative, in agreement with MA cases constituted only of elongated, fibroblast-like cells (Burger and Scheithauer, 2007). Similarly, positive immunostaining restricted to intima endothelial cells excludes the participation of endothelial hyperplasia in the genesis of perivascular proliferation.

The maintenance of the cortical cytoarchitecture in MA depends on the ratio of meningothelial/fibroblast-like perivascular proliferation to brain parenchyma, which is obscured proportionally by downgrowth of the lesion. The maintenance of the cortical cytoarchitecture associated with the proliferation of elongated, fibroblast-like cells in the present case, without the presence of meningothelial cells, suggests that it may correspond to an initial evolutive stage of MA (Suarez et al., 2006; Wiebe et al., 1999). On the other hand, the ischemic neuronal lesions observed could be explained by the status epilepticus presented by the patient.

In most cases, treatment is surgical, involving resection of the lesion to control the seizures. However, seizures can persist in many patients, with control achieved by administration of antiepileptic drugs, a fact that suggests an extrasional epileptogenic area. Surgical resection was not possible in the present case due to the extensive cortical compromise.

In conclusion, diagnosis of MA is difficult based only on imaging exams, but it should be considered in lesions affecting the brain cortex, associated with calcifications or not. Differential diagnoses of MA include vascular malformations, meningioma, gliomas, and granulomatous process. Whenever possible, the treatment of choice is the surgical approach, often in association with antiepileptic drugs. In cases involving extensive multiple lesions without calcifications, alterations in the imaging exams can be suggestive of encephalitis.

REFERENCES
1. Aizpuru RN, Quencer RM, Norenberg M, Altman N, Smirniotopoulos J. Meningioangiomatosis: Clinical, radiologic, and histopathologic correlation. Radiology 1991;179:819-21.
2. Basso P, Nazaum F. Report of a case of central and peripheral neurofibromatosis. J Nerv Ment Dis 1915;42:785-96.
3. Goates JJ, Dickson DW, Horoupian DS. Meningioangiomatosis: An immunocytochemical study. Acta Neuropathol 1991;82:527-32.
4. Halper J, Scheithauer BW, Okazaki H, Laws ER Jr. Meningioangiomatosis: A report of six cases with special reference to the occurrence of neurofibillary tangles. J Neuropathol Exp Neurol 1986;45:426-36.
5. Honavar M, Meldrum BS. Epilepsy. In: Graham DI, Lantos PL, editors. Greenfield’s Neuropathology. 7th ed. London: Arnold; 2002. p. 899-941.
6. Jallo GI, Kothbauer K, Mehta Y, Abbott R, Epstein F. Meningioangiomatosis without neurofibromatosis: A clinical analysis. J Neurol Surg 2005;103 Suppl 4:319-24.
7. Kasanustik V, Brown WJ. Meningioangiomatosis in the absence of von Recklinghausen’s disease. Surg Neurol 1981;15:71-5.
8. Kollia S, Crane KR, Ball WS Jr, Prenger EC, Ballard ET. Meningioangiomatosis of the brain stem. Case report. J Neurol Surg 1994;80:732-5.
9. Prayson RA. Meningioangiomatosis. A clinicopathologic study including MIB I immunoreactivity. Arch Pathol Lab Med 1995;119:1061-4.
10. Rubenstein LI. Tumors of the central nervous system. In: Atlas of Tumor Pathology. 2nd series, fascicle 6. Washington DC: Armed Forces Institute of Pathology; 1972. p. 252-307.
11. Savarganes P, Chen S, Bhuiya T, Valderrama E, Bloom T, Farmer PM. Meningioangiomatosis: Report of three cases and review of the literature. Ann Clin Lab Sci 2003;33:115-8.
12. Stemmer-Rachaminov AO, Horgan MA, Taratuto AC, Munoz DG, Smith TW, Froesch MP et al. Meningioangiomatosis is associated with neurofibromatosis 2 but not with somatic alterations of the NF2 gene. J Neuropathol Exp Neurol 1997;56:485-9.
13. Suarez-Gauthier A, Gomez BM, Garcia-Garcia E, Hinojosa J, Ricoy JR. Meningioangiomatosis: Descripción de dos casos y revisión de la literatura. Neurocirugía 2006;17:250-6.
14. Takekshi M, Nakayama V, Nakayori F, Nakano T, Sugiyama K, Inai K. Meningioangiomatosis occurring in a young male without neurofibromatosis: With special reference to its histogenesis and loss of heterozygosity in the NF2 gene region. Am J Surg Pathol 2002;26:125-9.
15. Tien RD, Osumi A, Oakes JW, Madden JF, Burger PC. Meningioangiomatosis: CT and MR findings. J Comput Assist Tomogr 1992;16:363-1.
16. Wang Y, Gao X, Yao ZW, Chen H, Zhu JJ, Wang SX, et al. Histopathological study of five cases with sporadic meningioangiomatosis. Neuropathology 2006;26:249-56.
17. Wiebe S, Munoz DG, Smith S, Lee DH. Meningioangiomatosis: A comprehensive analysis of clinical and laboratory features. Brain 1999;12:709-26.
18. Worster-Drought C, Dickson WEC, McMenemey WH. Multiple meningeal and perineural tumours with analogous changes in the glia and ependyma (neurofibromatosis), with report of 2 cases. Brain 1937;60:85-117.